Trial No.: AstraZeneca D8488C00001 Concerto
A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
©2018 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.